Suven Pharmaceuticals News and Resources

Suven Pharmaceuticals has announced the acquisition of a controlling stake in NJ Bio Inc., a Princeton-based CRDMO specialising in Antibody-Drug Conjugates (ADCs) and related emerging modalities. The investment, worth $64.4 million, aligns with Suven’s strategic vision of offering end-to-end solutions

Suven Pharmaceuticals has announced a strategic investment in Sapala Organics, a Hyderabad-based Contract Development and Manufacturing Organisation (CDMO) specialising in Oligo drugs and nucleic acid building blocks. The agreement is subject to regulatory approvals and conditions. Sapala Organics is a key